A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other solid tumors.
At present, including the new FDA licence for BL-M17D1, the Company has a total of six projects that have been licensed by the FDA to conduct clinical research, and the other five are: BL-B01D1, BL-M07D1, SI-B001, BL-M05D1, BL-M11D1 clinical trials in the United States.
Learn more about our HER2 catalog.
